NCT00319631撤回不适用
Role of Vascular Endothelial Growth Factor (VEGF) in Acute Lung Injury/Adult Respiratory Distress Syndrome (ARDS)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 1
研究概览
简要总结
Understanding the role VEGF plays in ARDS consequently provides an ideal opportunity to discover new therapies for ARDS.
详细描述
In previous lab experiments, we observed evidence of pulmonary edema following alveolar epithelial overexpression of VEGF, suggesting a potential role for VEGF in ARDS. In addition, we found that preventing VEGF from reaching its target receptor(s) by overexpressing a soluble form of a VEGF receptor protein prevents edema formation.
These observations heighten the plausibility of VEGF playing an important role in the development of increased pulmonary capillary permeability during acute lung injury. Understanding this role VEGF plays in ARDS consequently provides an ideal opportunity to discover new therapies for ARDS.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients that meet the American-European Consensus Conference criteria for ARDS [(1) Widespread pulmonary infiltrates; (2) Pulmonary capillary wedge pressure 18 mmHg; (3) PaOz/FiO; ratio 200; (4) compatible history], or acute lung injury [same as ARDS, but PaOz/FiOz ratio 300], or are at increased risk for developing acute lung injury because of sepsis, pancreatitis, trauma, acid aspiration, radiation or chemotherapy-induced lung toxicity, and near drowning. Pulmonary edema is divided into two broad categories: hydrostatic or cardiogenic and increased-permeability or noncardiogenic edema
- •Since ARDS is noncardiogenic in origin, patients with pulmonary edema due to congestive heart failure will serve as a control group.
- •Inpatients that are endotracheally intubated.
- •Patients that are able to provide informed consent or informed consent is granted by a family member or legal health care proxy.
- •Males or females that are 18 years or older.
排除标准
- •Individuals who are too hypoxemic for bronchoscopy to be performed safely. Patients requiring V\0z > 0.7 and/or PEEP 15 will be excluded.
- •If the patient will be unable to tolerate bronchoscopy because of severe
- •acidosis, tension pneumothorax, active bronchospasm, hemodynamically significant cardiac arrhythmia, or intractable shock as defined as the inability to maintain a mean arterial pressure 60 mmHg or severe uncorrectable bleeding diathesis (tendency) or as otherwise determined by the pulmonary physician.
- •Females who are pregnant will not be accepted into the study.
- •Patients with recent (48 hours) acute myocardial infraction will not be accepted into the study.
- •Patients with a history of adverse reactions to lidocaine will be not be accepted into the study.
- •Patients who lack capacity to give informed consent due to acute panic attack, "intensive care unit" psychosis or other psychologic dysfunction.
研究者
研究点 (1)
Loading locations...
相似试验
撤回
4 期
Use of Bevacizumab to Modulate the Outcomes of Trabeculectomy SurgeryGlaucomaNCT01229202Nova Scotia Health Authority
已完成
1 期
Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD TrialNeovascular Age-related Macular DegenerationWet Age-related Macular DegenerationNCT03066258REGENXBIO Inc.42
招募中
1 期
Study of VEGF-A Targeting NIR-II Fluorescence Endoscopy in the Gastrointestinal TractGastrointestinal CarcinomaDysplasiaGastrointestinal PolypNCT06430372Institute of Automation, Chinese Academy of Sciences30
已完成
不适用
Vascular Endothelial Growth Factor (VEGF), Platelet Derived Growth Factor (PDGF), Hepatocyte Growth Factor (HGF) in Patients With Acute Coronary Syndrome (ACS)Acute Coronary SyndromeNCT00844987National Institute of Cardiology, Warsaw, Poland120
已完成
3 期
Anti-VEGF Treatment for Prevention of PDR/DMEDiabetic Macular EdemaDiabetic RetinopathyNCT02634333Jaeb Center for Health Research399